Diana Harshbarger

To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.

This bill, known as the Cosmetic Act, proposes to provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs. It has been referred to committee for review and possible markup.

Michael Enzi Voluntary Protection Program Act of 2025

This bill, known as the Michael Enzi Voluntary Protection Program Act of 2025, addresses Michael Enzi Voluntary Protection Program Act of 2025. It has been introduced and awaits committee review.

ADAS Functionality and Integrity Act

This bill, known as the ADAS Functionality and Integrity Act, addresses ADAS Functionality and Integrity Act. It has been introduced and awaits committee review.

DRIVER Act

This house bill addresses dRIVER Act. It has been referred to committee for review and possible markup.

Pregnancy.Gov Act

This house bill addresses pregnancy.Gov Act. It has been referred to committee for review and possible markup.

Seniors’ Access to Critical Medications Act of 2025

This bill, known as the Access to Critical Medications Act of 2025, addresses Seniors’ Access to Critical Medications Act of 2025. It has been reported by committee and advances toward a floor vote.